REGULATION OF VASCULAR ALPHA1--ADRENERGIC RESPONSES
Project Number5R01HL042539-10
Contact PI/Project LeaderCOLUCCI, WILSON S.
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Alpha1-Adrenergic receptors (alpha1-AR) play an important role in
mediating the effects of catecholamines on the physiology, phenotype and
growth of vascular smooth muscle cells (VSMC). We recently found that
agonist-induced down-regulation of alpha1B-AR mRNA in VSMC from the rabbit
aorta (RbSMC) is due to a post-transcriptional, protein kinase C-mediated
decrease in the mRNA stability. Three subtypes of the alpha1-AR (alpha1B,
alpha1C and alpha1D) have been cloned, and appear to be heterogeneous with
regard to tissue distribution and coupling to second messengers and
physiologic responses. There is uncertainty about the relationship
between the 3 cloned subtypes and pharmacologically-defined subtypes, and
there is no information about the role of the alpha1-AR subtypes in
mediating the effects of alpha-adrenergic agonists on growth in VSMC. The
goals of this proposal are: 1) to identify the cis-elements that determine
the susceptibility of alpha1B-AR mRNA to phorbol ester-induced
destabilization, 2) to demonstrate and characterize a phorbol ester-
stimulated binding factor for alpha1B-AR mRNA, and 3) to elucidate the
coupling of the cloned alpha1B and alpha1C-AR subtypes to second
messengers and growth in VSMC. In SPECIFIC AIM I we will test the
hypothesis that phorbol ester-induced destabilization of alpha1B-AR mRNA
requires the presence of cis-acting structural element(s) in the mRNA by
testing for the ability of phorbol esters to destabilize wild-type and
modified alpha1B-AR mRNA transcripts expressed in cultured cells. In
SPECIFIC AIM II we will test the hypothesis that alpha1B-AR mRNA is
destabilized by the phorbol ester-induced binding of a cell-specific,
trans-acting factor by using RNA gel shift and ultraviolet cross-linking
assays to demonstrate phorbol ester-induced binding of a factor in RbSMC
cytosol to in vitro-transcribed rabbit alpha1B-AR mRNA. In SPECIFIC III
we will use both pharmacologic methods and subtype-specific antisense
oligonucleotides directed against alpha1B and alpha1C-AR mRNA to test the
hypothesis that these alpha1-AR subtypes are coupled to distinct second
messenger pathways and exert cooperate effects on VSMC growth (protein and
DNA synthesis) and growth-related signalling pathways (activation of
mitogen-activated protein kinase, and induction of c-fos and transforming
growth factor-beta1 mRNAs).
No Sub Projects information available for 5R01HL042539-10
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HL042539-10
Patents
No Patents information available for 5R01HL042539-10
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HL042539-10
Clinical Studies
No Clinical Studies information available for 5R01HL042539-10
News and More
Related News Releases
No news release information available for 5R01HL042539-10
History
No Historical information available for 5R01HL042539-10
Similar Projects
No Similar Projects information available for 5R01HL042539-10